Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 3 32Phase 1 20Phase 1/2 16Phase 2/3 5Phase NA 2

Status

Recruiting 4Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Pancreatic Neoplasms 1Mediastinal Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 14Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 8Radiation 8Platinum 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Pemetrexed 7Drug Therapy 7Dexamethasone 7Temozolomide 6Ipilimumab 6Surgical Procedures, Operative 5Rituximab 5Radiotherapy, Intensity-Modulated 5Prednisone 5Cytarabine 5Cyclophosphamide 5Biopsy 5130-nm albumin-bound paclitaxel 5venetoclax 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × 130-nm albumin-bound paclitaxel × 90 days × Clear all
NCT07365319 2026-05-20

TeLuRide-008

Eikon Therapeutics

Phase 2/3 Recruiting
750 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-05-18

MountainTAP-29

Bristol-Myers Squibb

Phase 2/3 Recruiting
590 enrolled
Thoracic

Lung Neoplasms

NCT06926868 2026-04-30

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Bristol-Myers Squibb

Phase 2/3 Recruiting
500 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07076121 2026-04-30

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Bristol-Myers Squibb

Phase 2/3 Recruiting
470 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Not yet recruiting
116 enrolled
Thoracic

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡